专利视角下胰高血糖素样肽-1受体激动剂发展态势分析

The development trend analysis of glucagon-like peptide-1 receptor agonists from a patent perspective

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1RA)具有多重生理作用和重大经济价值,对当今社会实施创新驱动发展具有重大意义。全球GLP-1RA类药物大多被国外大型制药企业垄断,亟需突破技术壁垒,实现相关药物的国产化进程。本文基于专利分析视角,检索全球专利数据,并从全球GLP-1RA专利总体态势、技术布局和专利质量分角度进行分析,包括全球申请趋势、地域分布、重点申请人、重点企业专利布局和核心产品专利布局等。通过统计分析发现,全球GLP-1RA专利数量快速增长,美国和欧洲专利申请较多,并且积极在全球主要国家和地区进行专利布局,专利质量较高;我国专利数量较多,但在专利布局和专利质量方面存在提升空间。建议参考国外发展经验,发挥自身优势,促进我国GLP-1RA技术发展和应用。

Glucagon-like peptide-1 receptor agonists(GLP-1RA)have multiple physiological effects and significant economic value,which are of great significance for implementing innovation-driven development.GLP-1RA drugs are mostly monopolized by large foreign pharmaceutical companies,and there is an urgent need to break through technological barriers and achieve the localization process of related drugs.Based on the perspective of patent analysis,this article retrieved global patent data of GLP-1RA and analyzed it from perspectives of global overall situation of the patents,technology layout,and patent quality,including global application trends,regional distribution,key applicants,key enterprise patent layout,and core product patent layout.Statistical analysis showed that the number of GLP-1RA patents had been growing rapidly,with larger patent applications in the United States and Europe,the pharmaceutical companies actively made patent layout in major countries and regions worldwide,and the patent quality was high.China has a larger number of patents,but there is room for improvement in patent layout and patent quality.It is recommended to refer to foreign development experience,leverage our own advantages,and promote the global development and application of GLP-1RA technology in China.